Publications by authors named "Moses Shongwe"
Article Synopsis
- Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved in November 2021 for use in virally suppressed adults in England and Wales, and the evaluation of its delivery processes took place across 12 clinics.*
-
- A total of 518 adults were approved for CAB + RPV LAI from February 2022 to December 2023, with 423 receiving at least one injection; the treatment had a median duration of 7.5 months and a high adherence rate of 97% for timely injections.*
-
- Results indicated only 0.7% experienced virological failure and 6% discontinued treatment, showcasing that effective clinic protocols and
